Bloomberg Intelligence
Rx Savings' Rea on Wide Gaps in EpiPen Drug Pricing (Audio)
This episode isn’t summarized yet
Create a free account and summarize it. In a few minutes you’ll have the key takeaways and a section-by-section summary.
Show notes
(Bloomberg) -- Taking Stock with Kathleen Hays and Pimm Fox. GUEST: HEALTHCARE: Michael Rea, CEO of Rx Savings Solutions, to discuss the wide gap in Mylan's EpiPen drug pricing between the UK ($69) and the US ($600.)
See omnystudio.com/listener for privacy information.